Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing

Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE

(2013) Nasim Mavaddat et al.   JNCI-Journal of the National Cancer Institute

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

(2013) Shahneen K Sandhu et al.   LANCET ONCOLOGY

BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years

(2012) L Robertson et al.   BRITISH JOURNAL OF CANCER

NSGC Practice Guideline: Risk Assessment and Genetic Counseling for Hereditary Breast and Ovarian Cancer

(2012) Janice L. Berliner et al.   Journal of Genetic Counseling

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

BRCA2 Mutations and Triple-Negative Breast Cancer

(2012) Peter Meyer et al.   PLoS One

Relative contributions of BRCA1 and BRCA2 mutations to “triple-negative” breast cancer in Ashkenazi Women

(2011) E. Comen et al.   BREAST CANCER RESEARCH AND TREATMENT

Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer

(2011) Anne-Renee Hartman et al.   CANCER

Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer

(2011) A. M. Gonzalez-Angulo et al.   CLINICAL CANCER RESEARCH

Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling

(2011) Grace Wang et al.   GENETICS IN MEDICINE

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

(2010) Daniel P. Silver et al.   JOURNAL OF CLINICAL ONCOLOGY

Expanding the Criteria forBRCAMutation Testing in Breast Cancer Survivors

(2010) Janice S. Kwon et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility

(2010) Mark E. Robson et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Basal Cytokeratin and Epidermal Growth Factor Receptor Expression Are Not Predictive of BRCA1 Mutation Status in Women With Triple-negative Breast Cancers

(2009) Laura C. Collins et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer

(2009) SR Young et al.   BMC CANCER

Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy

(2009) Tomasz Byrski et al.   JOURNAL OF CLINICAL ONCOLOGY

Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support

(2008) Paul A. Harris et al.   JOURNAL OF BIOMEDICAL INFORMATICS

Clinical and Pathologic Characteristics of Patients WithBRCA-Positive andBRCA-Negative Breast Cancer

(2008) Deann P. Atchley et al.   JOURNAL OF CLINICAL ONCOLOGY